FDA 483 - GlaxoSmithKline Manufacturing S.p.A. - May 15, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of GlaxoSmithKline Manufacturing SpA, a drug substance and drug product manufacturer, revealed significant issues with environmental control and sterilization processes. The firm failed to adequately control mold in classified production rooms, showing an increasing trend of mold recoveries and ineffective corrective actions. Additionally, the acceptance criteria for biological indicators used in sterilization cycles were found to be insufficient to ensure proper sterility assurance.
ID · ac7ed7b6-0c73-4492-9e81-44547f9e5440